{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:58:42Z","timestamp":1786993122879,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jocn.2021.11.010","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T19:47:52Z","timestamp":1638560872000},"page":"44-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Is myasthenia gravis a contraindication for botulinum toxin?"],"prefix":"10.1016","volume":"95","author":[{"given":"Qian","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyi","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jocn.2021.11.010_b0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrmicro3295","article-title":"Botulinum neurotoxins: genetic, structural and mechanistic insights","volume":"12","author":"Rossetto","year":"2014","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.jocn.2021.11.010_b0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol Rev"},{"issue":"5","key":"10.1016\/j.jocn.2021.11.010_b0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis-autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"10.1016\/j.jocn.2021.11.010_b0020","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00702-010-0481-9","article-title":"Subclinical myasthenia gravis causing increased sensitivity to botulinum toxin therapy","volume":"117","author":"Dressler","year":"2010","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"10.1016\/j.jocn.2021.11.010_b0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"5\u20136","key":"10.1016\/j.jocn.2021.11.010_b0030","first-page":"E184","article-title":"The use of intra-detrusor onabotulinumtoxinA in patients with myasthenia gravis","volume":"10","author":"Wright","year":"2016","journal-title":"J Neural Transm (Vienna)"},{"issue":"3A","key":"10.1016\/j.jocn.2021.11.010_b0035","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1590\/S0004-282X1999000400024","article-title":"Treatment of cervical dystonia with botulinum toxin in a patient with myasthenia gravis","volume":"57","author":"Gon\u00e7alves","year":"1999","journal-title":"Arq Neuropsiquiatr"},{"issue":"Suppl. 1","key":"10.1016\/j.jocn.2021.11.010_b0040","first-page":"S72","article-title":"Botulinum Toxin for Cervical Dystonia in a Patient with Myasthenia Gravis","volume":"33","author":"Della Coletta","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2021.11.010_b0045","doi-asserted-by":"crossref","unstructured":"K. Hara A. Matsuda Y. Kitsukawa K. Tanaka M. Nishizawa A. Tagawa Botulinum toxin treatment for blepharospasm associated with myasthenia gravis Mov Disord 22 9 2007 1363 1364.","DOI":"10.1002\/mds.21558"},{"issue":"3","key":"10.1016\/j.jocn.2021.11.010_b0050","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/mds.870090319","article-title":"Botulinum toxin for spasmodic torticollis in a patient with myasthenia gravis","volume":"9","author":"Emmerson","year":"1994","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.jocn.2021.11.010_b0055","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1212\/01.WNL.0000165997.77985.32","article-title":"Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia","volume":"64","author":"Fasano","year":"2005","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jocn.2021.11.010_b0060","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0161-6420(80)35127-0","article-title":"Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery","volume":"87","author":"Scott","year":"1980","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.jocn.2021.11.010_b0065","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00702-015-1478-1","article-title":"Botulinum toxin drugs: brief history and outlook","volume":"123","author":"Dressler","year":"2016","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"10.1016\/j.jocn.2021.11.010_b0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/toxins10040143","article-title":"Antipruritic Effects of Botulinum Neurotoxins","volume":"10","author":"Gazerani","year":"201829104","journal-title":"Toxins (Basel)"},{"issue":"4","key":"10.1016\/j.jocn.2021.11.010_b0075","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00415-018-8759-1","article-title":"Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy","volume":"265","author":"Dressler","year":"2018","journal-title":"J Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.jocn.2021.11.010_b0080","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.4111\/icu.2020.61.S1.S33","article-title":"Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis","volume":"61","author":"Chen","year":"2020","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.jocn.2021.11.010_b0085","doi-asserted-by":"crossref","unstructured":"Chen CL, Meng E. Can Botulinum Toxin A Play A Role In Treatment Of Chronic Pelvic Pain Syndrome In Female Patients?-Clinical and Animal Evidence. Toxins (Basel) 2020, 10, 12(2).","DOI":"10.3390\/toxins12020110"},{"issue":"10","key":"10.1016\/j.jocn.2021.11.010_b0090","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3389\/fphar.2019.01618","article-title":"Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder","volume":"15","author":"Gong","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jocn.2021.11.010_b0095","doi-asserted-by":"crossref","unstructured":"Cavallini M, Cirillo P, Fundar\u00f2 SP, Quartucci S, Sciuto C, Sito G, et al. Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies. Dermatol Surg 2014;40(5):525-36.","DOI":"10.1111\/dsu.12463"},{"issue":"19","key":"10.1016\/j.jocn.2021.11.010_b0100","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jocn.2021.11.010_b0105","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/mus.880140711","article-title":"Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes","volume":"14","author":"Lange","year":"1991","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.jocn.2021.11.010_b0110","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/1531-8257(200007)15:4<736::AID-MDS1023>3.0.CO;2-9","article-title":"Myasthenia gravis after botulinum toxin A for Meige syndrome","volume":"15","author":"Tarsy","year":"2000","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.jocn.2021.11.010_b0115","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00417-005-0130-4","article-title":"Systemic effect of local and small-dose botulinum toxin injection to unmask subclinical myasthenia gravis","volume":"244","author":"Iwase","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.jocn.2021.11.010_b0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4274\/tnd.02703","article-title":"Myasthenia Gravis after Botulinum Toxin Type A Injection","volume":"22","author":"Durmu\u015f Tek\u00e7e","year":"2016","journal-title":"Turk J Neurol"},{"issue":"9143","key":"10.1016\/j.jocn.2021.11.010_b0125","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/S0140-6736(05)79896-2","article-title":"Myasthenic crisis after botulinum toxin","volume":"352","author":"Borodic","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jocn.2021.11.010_b0130","first-page":"102","article-title":"Development of myasthenia gravis after botulinum toxin management in myofascial pain syndrome","volume":"22","author":"Mu\u00f1oz Vel\u00e1zquez M\u00aa","year":"2015","journal-title":"Revista de la Sociedad Espa\u00f1ola del Dolor"},{"key":"10.1016\/j.jocn.2021.11.010_b0135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.atherosclerosissup.2017.05.016","article-title":"Therapeutic Plasma Exchange in a rare case myasthenic crisis after BTX injection","volume":"30","author":"Chegini","year":"2017","journal-title":"Atheroscler Suppl"},{"issue":"12","key":"10.1016\/j.jocn.2021.11.010_b0140","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.jocn.2015.05.032","article-title":"Myasthenia gravis exacerbation with low dose ocular botulinum toxin for epiphoria","volume":"22","author":"Watts","year":"2015","journal-title":"J Clin Neurosci"},{"issue":"2","key":"10.1016\/j.jocn.2021.11.010_b0145","doi-asserted-by":"crossref","DOI":"10.1002\/mds.21213","article-title":"Botulinum toxin type A therapy in a patient with cervical dystonia and amyotrophic lateral sclerosis","volume":"22","author":"Singer","year":"2007","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.jocn.2021.11.010_b0150","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3390\/toxins11070381","article-title":"Botulinum Toxin Type A and Physiotherapy in Spasticity of the Lower Limbs Due to Amyotrophic Lateral Sclerosis","volume":"11","author":"Marvulli","year":"2019","journal-title":"Toxins (Basel)"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821005580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821005580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:28:03Z","timestamp":1760822883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586821005580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":30,"alternative-id":["S0967586821005580"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2021.11.010","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is myasthenia gravis a contraindication for botulinum toxin?","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2021.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}